Ministry of Health and Family Welfare
UPDATES ON COVID-19 AS ON 11.7.2020
Standard of care for Clinical Management Strategy for COVID-19
Standard of care for Clinical Management Strategy for COVID-19
Posted On: 11 JUL 2020 4:51PM by PIB Delhi
The approach for treatment of COVID-19 is largely
based on asymptomatic and supportive care, since there is no cure as yet.
Maintaining good hydration is also essential. Based on severity of
symptoms, COVID-19 can be categorised into 3 groups: mild, moderate and
severe. In a Video Conference with States on 10.07.2020 and a virtual
meeting on “COVID Case Management by State / UT Centres of Excellence” on
10.07.202, ICMR and AIIMS, New Delhi emphasised the theme that in the absence
of a cure, the standard of care treatment for mild, moderate and severe cases
as described in the Clinical Management Protocol of Ministry of Health &
Family Welfare (MoHFW), would be most effective.
For moderate and severe cases, adequate oxygen
support, appropriate and timely administration of anti coagulants and widely
available and inexpensive corticosteroids, in accordance with the protocol, can
be considered to be the mainstay of COVID-19 therapy. For mild cases,
which are nearly 80% of the total cases, Hydroxychloroquine (HCQ) has been
recommended. The standard of care treatment strategies have shown to
yield positive results.
The pursuit of an effective treatment for COVID-19
has also resulted in repurposing of several drugs which are not a part of the
main Clinical Management Protocol but have been indicated as “investigational
therapies”. These can be used in specific sub-groups of patients on the
basis of informed and shared decision making with the patient before
prescribing these drugs. These drugs have still not been approved by the
Drugs Controller General of India (DCGI) and are only permitted for restricted
Emergency Use for COVID-19. The States as well as the Medical College
hospitals designated as Centres of Excellence were reminded by ICMR and AIIMS that
their indiscriminate use or use in conditions for which they are not desirable,
may cause more harm than good.
The States were also told that the available
evidence for Remdesivir suggests that it may decrease the time for clinical
improvement when used in moderate to severe cases. However, there have
been no benefits in terms of reduced mortality. It has to be used with
extreme caution due to its potential for serious adverse effects including
liver and kidney injury. Similarly, for Tocilizumab studies have not
shown any benefits in mortality reduction. However, if used for patients
with severe conditions, proper informed consent is required. Rampant use
is to be discouraged since the effect of the drug is directed at the ‘cykotine
storm’.
All the ‘investigational therapies’ are required to
be carried out only in proper health care facilities where close monitoring of
patients is possible so that potential complications can be managed. ICMR
strongly recommended that the focus of clinical management should continue to
remain on oxygen therapy (including high flow nasal oxygen), steroids (which
are widely available and inexpensive), appropriate & timely administration
of anti-coagulants and high quality supportive care, including mental health
counselling for patients and families, proning, management of pre-existing
illness and palliation of symptoms.
****
MV/SG
(Release ID: 1637996) Visitor Counter : 71
Ministry of Health and Family Welfare
Recovered cases cross 5 lakhs; outnumber active cases by more than 2.31
lakhs
RECOVERY RATE nearly 63%
RECOVERY RATE nearly 63%
Posted On: 11 JUL 2020 4:37PM by PIB Delhi
A series of pro-active, pre-emptive and coordinated measures have been
taken by the Centre and the State governments for containment and prevention of
COVID-19. Coupled with effective implementation of containment zones,
surveillance activities, timely diagnosis and effective clinical management of
COVID-19 cases, the cumulative total number of recovered cases among COVID-19
patients has crossed the 5 lakh mark today. 5,15,385 COVID-19 patients have so
far been cured and discharged. The recovered cases outnumber the COVID-19
active cases by 2,31,978.
With this progressively widening gap, the recovery rate has further
improved to 62.78%. During the last 24 hours, 19,870 COVID-19 patients have
been cured and discharged.
There are 2,83,407 active cases and all are under medical supervision
either in the central and state government hospitals for severe cases, and in
home isolation for pre-symptomatic patients and those showing moderate symptoms.
Recent policy changes like allowing all registered medical practitioners to
recommend testing for COVID and introduction of Rapid Antigen point of care
testing along with RT-PCR has substantially bolstered the COVID-19 tests in the
country. So far, 1,13,07,002 samples have been tested through the collective
public and private labs under ICMR’s diagnostic network of 1180 labs in the
country. While those in the public sector have appreciably increased to 841
labs, the number of private labs has also been strengthened to a total of 339.
The per day tests are demonstrating a steep upward trend with 2,82,511 samples
tested yesterday. As on date, the Test per Million (TPM) for the country stands
at 8193.
• Real-Time RT PCR based testing labs: 620
(Govt: 386 + Private: 234)
• TrueNat based testing labs: 463 (Govt: 420 + Private: 43)
• CBNAAT based testing labs: 97
(Govt: 35 + Private: 62)
For all authentic & updated information on COVID-19 related technical
issues, guidelines & advisories please regularly visit:
https://www.mohfw.gov.in/ and @MoHFW_INDIA.
Technical queries related to COVID-19 may be sent to
technicalquery.covid19@gov.in and other queries on ncov2019@gov.in and
@CovidIndiaSeva .
In case of any queries on COVID-19, please call at the Ministry of Health
& Family Welfare helpline no.: +91-11-23978046 or 1075 (Toll-free). List of
helpline numbers of States/UTs on COVID-19 is also available at
****
MV
(Release ID: 1637987) Visitor Counter : 120
Ministry of Health and Family Welfare
DCGI gives Nod for Restricted Emergency Use to Itolizumab for moderate to
severe COVID-19 patients
Posted On: 11 JUL 2020 12:22PM by PIB Delhi
Itolizumab (rDNA origin), a monoclonal antibody
which was already approved for severe chronic plaque psoriasis, has now been
granted Restricted Emergency Use authorisation by the Drugs Controller General
of India (DCGI) based on clinical trials data.
M/s Biocon has been manufacturing and marketing
this drug for the treatment of patients with moderate to severe chronic plaque
psoriasis since 2013 under brand name Alzumab. This indigenous drug has now
been repurposed for COVID-19.
M/s Biocon has presented the Phase II clinical
trial results generated in COVID-19 patients to DCGI. The results of these
trials were deliberated in the Subject Expert Committee of DCGI’s office.
Details of primary endpoint of mortality, other key
endpoints of lung function such as improvement in PaO2 and O2 saturation were
presented. Key inflammatory markers IL-6, TNFα etc., were presented to have
reduced significantly with the drug thereby preventing hyper- inflammation in
COVID-19 patients.
After detailed deliberation and taking into account
the recommendations of the Committee, DCGI has decided to grant permission to
market the drug under Restricted Emergency Use of the drug for the treatment of
Cytokine Release Syndrome (CRS) in moderate to severe Acute Respiratory
Distress Syndrome (ARDS) patients due to COVID-19, subject to some conditions
like informed consent of patients, a risk management plan, to be used in
hospital set up only etc.
The average cost of treatment with this indigenous
drug i.e Itolizumab is also lesser than comparable drugs which are part of the
“Investigational Therapies” indicated in the Clinical Management Protocol for
COVID-19 of the Ministry of Health and Family Welfare.
.
****
MV
(Release ID: 1637926) Visitor Counter : 1013
No comments:
Post a Comment